Form D · Pharmaceuticals

Annovation BioPharma, Inc.

Cambridge, MA · CIK 0001517294

Offering snapshot reported Apr 17, 2014 · SEC filing

Reported sold
$8M
Offering amount: $11M
Investors reported
10
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 23, 2012
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$4M$8MJul 25, 2012: $2,022,701.00Jul 25, 2012Apr 17, 2014: $8,000,201.00Apr 17, 2014

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$2,022,701 → $8,000,201

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 17, 2014Amendment$8,000,201$5,977,500vs Jul 25, 201210SEC filing
Jul 25, 2012Initial$2,022,701No comparison10SEC filing
May 17, 2011Initial$375,000No comparison11SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-181765

Source: Form D, filed Apr 17, 2014. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Nicholas Barker Director
Carl Berke Director, Executive
Jason Campagna Director
Jean Francois Formela Director
David Grayzel Director, Executive
Ankit Mahadevia Director
Douglas Raines Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
C/O Atlas Venture 25 First Street, Suite 303
Cambridge, MA, 02141